文献速递肝病消化道肿瘤与早癌

四元纳米颗粒实现硼替佐米的持续释放用于肝细胞癌治疗

Quaternary nanoparticles enable sustained release of bortezomib for hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2022-06-24

研究通过40例肝细胞癌患者来源类器官的高通量药物筛选,鉴定出硼替佐米(BTZ)为高细胞毒性小分子,并利用闪速纳米复合/纳米沉淀工艺制备持续释放BTZ纳米颗粒(BTZ-NP)。BTZ-NP在体外实现30天持续释放,在三种肝细胞癌动物模型中有效控制肿瘤大小并改善生存,且经肝动脉递送时同样有效,效果优于多柔比星药物洗脱珠。作者结论认为BTZ-NP通过局部递送为肝细胞癌提供了强效且安全的治疗,结果值得进一步开展临床前研究以推进人体临床试验。

要点

  • 高通量筛选40例肝细胞癌患者来源类器官,鉴定BTZ为高细胞毒性小分子。
  • BTZ-NP体外持续释放BTZ达30天。
  • 三种肝细胞癌动物模型中BTZ-NP控制肿瘤并改善生存,优于多柔比星洗脱珠。

核心结论

  • BTZ-NP通过局部递送为肝细胞癌提供强效且安全的治疗。
  • 这些结果值得进一步开展临床前研究以推进该技术进入人体临床试验。

研究设计与样本

  • 研究采用40例肝细胞癌患者来源类器官进行高通量药物筛选。
  • 利用闪速纳米复合/纳米沉淀工艺设计并制备持续释放BTZ纳米颗粒(BTZ-NP)。
  • 在三种肝细胞癌动物模型中测试BTZ-NP的体内抗肿瘤效果。

主要发现

  • BTZ-NP制剂在体外显示BTZ持续释放30天。
  • BTZ-NP在三种肝细胞癌动物模型中有效控制肿瘤大小并改善生存。
  • 经肝动脉递送BTZ-NP时同样有效。
  • BTZ-NP效果优于多柔比星药物洗脱珠治疗。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出这些结果值得进一步开展临床前研究以推进该技术进入人体临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related mortality in the world. Over the past two decades, there has been minimal improvement in therapies as well as clinical outcomes for patients with Barcelona Clinic Liver Cancer (BCLC)-B. These patients are treated with local interventions, including transarterial chemoembolization. Current methodologies only allow sustained intratumoral release measured in hours. Methodologies to allow sustained local release of the drug cargo over days to weeks are acutely needed. We hypothesize that tumor response as well as outcomes of patients with BCLC-B can be improved through utilization of a highly cytotoxic agent delivered with a sustained release platform. APPROACH AND RESULTS: High-throughput drug screening across 40 HCC patient-derived organoids identified bortezomib (BTZ) as a highly cytotoxic small molecule for HCC. We designed and manufactured sustained release BTZ nanoparticles (BTZ-NP) using a flash nanocomplexation/nanoprecipitation process. We quantified the release profile and tested the anti-tumoral effects in vivo. The BTZ-NP formulation demonstrated a sustained release of BTZ of 30 days. This BTZ-NP formulation was highly effective in controlling tumor size and improved survival in vivo in three animal models of HCC, including when delivered via the hepatic artery, as we envision its delivery in patients. In addition, the BTZ-NP formulation was superior to treatment with doxorubicin-drug eluting beads. CONCLUSIONS: The BTZ-NP formulation provides a potent and safe treatment of HCC via a localized delivery approach. These results warrant additional preclinical studies to advance this technology to human clinical trials.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Li L, Zhang Y, Zhou Y, et al. Quaternary nanoparticles enable sustained release of bortezomib for hepatocellular carcinoma. Hepatology. 2022. PMID: 35596926. doi:10.1002/hep.32584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。